ArticleNature communications2026
Targeting phenol-soluble modulin α3-driven M1 macrophage polarization and necroptosis mitigates MRSA infection in mice.
Article in Nature communications, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
Abstract
The growing antibiotic resistance and high mortality rates associated with methicillin-resistant Staphylococcus aureus (MRSA) pose a global health threat, highlighting the urgent need for novel therapeutic strategies. Phenol-soluble modulin α3 (PSMα3) is a critical virulence factor in MRSA pathogenesis and immune evasion. However, its underlying mechanisms remain unclear. Here, we demonstrate that PSMα3 promotes both M1 macrophage polarization and necroptosis. These processes are mechanistically linked through an interaction between the interferon-stimulated gene factor 3 (ISGF3) and necrosome complexes, with formyl peptide receptor 2 (FPR2) serving as the key receptor. Based on this mechanism, we show that targeting signal transducer and activator of transcription 1 (STAT1), a key component of the ISGF3 complex, with the clinically approved drug fludarabine effectively mitigates MRSA infection in murine sepsis and pneumonia models. These findings reveal the mechanisms of MRSA pathogenesis and highlight the potential of anti-virulence strategies as innovative therapeutic approaches against MRSA infections.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.